SurModics, Inc.
SRDX
$34.62
$0.541.59%
| Weiss Ratings | SRDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | C | |||
| Rating Factors | SRDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Fair | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | SRDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.99 | |||
| Price History | SRDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 7.12% | |||
| 30-Day Total Return | 25.94% | |||
| 60-Day Total Return | 5.58% | |||
| 90-Day Total Return | 1.08% | |||
| Year to Date Total Return | -2.64% | |||
| 1-Year Total Return | 84.05% | |||
| 2-Year Total Return | -6.43% | |||
| 3-Year Total Return | -35.33% | |||
| 5-Year Total Return | -9.44% | |||
| 52-Week High % Change | -12.15% | |||
| 52-Week Low % Change | 106.19% | |||
| Price | SRDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $39.41 | |||
| 52-Week Low Price | $16.79 | |||
| 52-Week Low Price (Date) | May 25, 2023 | |||
| 52-Week High Price (Date) | Sep 11, 2023 | |||
| Valuation | SRDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 493.68M | |||
| Enterprise Value | 486.40M | |||
| Price/Earnings (TTM) | 36.33 | |||
| Earnings Per Share (TTM) | 0.95 | |||
| Earnings Per Share Growth | -136.93% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 3.43 | |||
| Price/Book (Q) | 3.98 | |||
| Enterprise Value/Revenue (TTM) | 3.40 | |||
| Price | $34.62 | |||
| Enterprise Value/EBITDA (TTM) | 17.88 | |||
| Enterprise Value/EBIT | 26.34 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | SRDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 14.18M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | SRDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 952 500 7000 | |||
| Address | 9924 West 74th Street Eden Prairie, MN 55344-3523 | |||
| Website | www.surmodics.com | |||
| Country | United States | |||
| Year Founded | 1979 | |||
| Profitability | SRDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 12.91% | |||
| Profit Margin | 9.44% | |||
| Management Effectiveness | SRDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 6.61% | |||
| Return on Equity | 11.92% | |||
| Income Statement | SRDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 142.96M | |||
| Total Revenue (TTM) | 142.96M | |||
| Revenue Per Share | $10.08 | |||
| Gross Profit (TTM) | 128.17M | |||
| EBITDA (TTM) | 27.20M | |||
| EBIT (TTM) | 18.46M | |||
| Net Income (TTM) | 13.50M | |||
| Net Income Avl. to Common (TTM) | 13.50M | |||
| Total Revenue Growth (Q YOY) | 17.50% | |||
| Earnings Growth (Q YOY) | 103.19% | |||
| EPS Diluted (TTM) | 0.95 | |||
| EPS Diluted Growth (Q YOY) | 103.17% | |||
| Balance Sheet | SRDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 40.94M | |||
| Cash Per Share (Q) | $2.89 | |||
| Total Current Assets (Q) | 84.26M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 123.95M | |||
| Current Ratio (Q) | 4.389 | |||
| Book Value Per Share (Q) | $8.69 | |||
| Total Assets (Q) | 182.81M | |||
| Total Current Liabilities (Q) | 19.20M | |||
| Total Debt (Q) | 33.66M | |||
| Total Liabilities (Q) | 58.86M | |||
| Total Common Equity (Q) | 123.95M | |||
| Cash Flow | SRDX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -10.80M | |||
| Cash from Financing (TTM) | -1.05M | |||
| Net Change in Cash (TTM) | 13.85M | |||
| Levered Free Cash Flow (TTM) | 21.97M | |||
| Cash from Operations (TTM) | 25.76M | |||
